
Company valuation, historical trends, and peer comparisons.
According to Cell Source, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 48.48M. This represents a change of 129.63% compared to the average of 21.11M of the last 4 quarters.
The mean historical Enterprise Value of Cell Source, Inc. over the last ten years is 31.09M. The current 48.48M Enterprise Value has changed 55.96% with respect to the historical average. Over the past ten years (40 quarters), CLCS's Enterprise Value was at its highest in in the June 2021 quarter at 70.48M. The Enterprise Value was at its lowest in in the September 2022 quarter at 7.20M.
Average
31.09M
Median
29.19M
Minimum
8.64M
Maximum
62.76M
Discovering the peaks and valleys of Cell Source, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 169.11%
Maximum Annual Enterprise Value = 62.76M
Minimum Annual Increase = -60.09%
Minimum Annual Enterprise Value = 8.64M
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 39.70M | 61.07% |
| 2024 | 24.65M | 4.48% |
| 2023 | 23.59M | -36.74% |
| 2022 | 37.29M | -11.97% |
| 2021 | 42.36M | -32.50% |
| 2020 | 62.76M | 86.05% |
| 2019 | 33.73M | 45.01% |
| 2018 | 23.26M | 169.11% |
| 2017 | 8.64M | -41.88% |
| 2016 | 14.87M | -60.09% |
The current Enterprise Value of Cell Source, Inc. (CLCS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
29.31M
5-year avg
33.52M
10-year avg
31.09M
Cell Source, Inc.’s Enterprise Value is less than Celularity Inc. (61.86M), greater than IN8bio, Inc. (-6512123.00), greater than CytoMed Therapeutics Limited (12.07M), greater than Xenetic Biosciences, Inc. (-1316770.00), less than Nkarta, Inc. (159.24M), greater than MiNK Therapeutics, Inc. (44.67M), greater than Tevogen Bio Holdings Inc. (26.82M), less than Cellectis S.A. (128.42M), less than Precision BioSciences, Inc. (135.58M), less than Legend Biotech Corporation (3.54B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 61.86M | $26.42M | |
| -6512123.00 | $9.27M | |
| 12.07M | $10.22M | |
| -1316770.00 | $5.15M | |
| 159.24M | $110.66M | |
| 44.67M | $53.48M | |
| 26.82M | $24.86M | |
| 128.42M | $111.39M | |
| 135.58M | $193.56M | |
| 3.54B | $3.94B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cell Source, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cell Source, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Cell Source, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Cell Source, Inc. (CLCS)?
What is the 3-year average Enterprise Value for Cell Source, Inc. (CLCS)?
What is the 5-year average Enterprise Value for Cell Source, Inc. (CLCS)?
How does the current Enterprise Value for Cell Source, Inc. (CLCS) compare to its historical average?